Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Ther Pat. 2010 May;20(5):625-46. doi: 10.1517/13543771003702424.

P2X purinergic receptor ligands: recently patented compounds.

Author information

  • 1University of Sydney, School of Chemistry, NSW 2006, Australia.

Abstract

IMPORTANCE OF THE FIELD:

P2X channels are ionotropic purinergic receptors that are currently under scrutiny as attractive targets for novel therapeutics in areas including chronic inflammation, pain and depression. Their wide expression in the CNS, recent advances in the biochemical and pharmacological properties as well as increasing numbers of patents published in this research domain demand a review in this field.

AREAS COVERED IN THIS REVIEW:

The patent literature covering novel drug-like antagonists for each P2X receptor subtype (P2X1R to P2X7R) up to December 2009 is described in this review article together with their recent highlights in pharmacology.

WHAT THE READER WILL GAIN:

Readers will gain an up-to-date overview of patents covering drug-like antagonists for seven P2X receptor subtypes within the last 4 years.

TAKE HOME MESSAGE:

P2X7R antagonists and other P2X inhibitors will probably be on the market for combating rheumatoid arthritis and other diseases. Some P2X7R antagonists are already in Phase I and II clinical trials.

PMID:
20205618
DOI:
10.1517/13543771003702424
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center